Market revenue in 2023 | USD 5.4 million |
Market revenue in 2030 | USD 7.4 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | New born screening (nbs) |
Fastest growing segment | CRO/Research |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | New Born Screening (NBS), Infectious Disease Testing, Therapeutic Drug Monitoring, CRO/Research, Other Applications, Forensics |
Key market players worldwide | Qiagen NV, PerkinElmer, Roche Holding AG, Shimadzu Corp, Ahlstrom-Munksjö, Danaher Corp, Centogene NV Ordinary Shares, Eastern Business Forms, Archimedlife |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dried blood spot collection cards market will help companies and investors design strategic landscapes.
New born screening (nbs) was the largest segment with a revenue share of 24.07% in 2023. Horizon Databook has segmented the Australia dried blood spot collection cards market based on new born screening (nbs), infectious disease testing, therapeutic drug monitoring, cro/research, other applications, forensics covering the revenue growth of each sub-segment from 2018 to 2030.
Excellent research facilities, world-class researchers, and a firm but flexible regulatory framework have made Australia a powerhouse of pharmaceutical and biotechnology innovation. According to the information published by Australian Trade and Investment Commission, Australia is becoming an attractive market for biotechnology companies with a booming network of over 470 biotechnology companies.
Increasing number of biotechnology & pharmaceutical players entering the market and comprehensive R&D projects being undertaken by them are likely to create a high requirement for DBS testing for therapeutic drug monitoring application.
The growing incidence of preterm births and infectious diseases, such as influenza & hepatitis, is increasing the economic burden on the Australian government, resulting in increased demand for effective DBS collection cards for early diagnosis of such diseases. The DBS screening test for hepatitis C is free of charge by the Hepatitis NSW organization in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia dried blood spot collection cards market , including forecasts for subscribers. This country databook contains high-level insights into Australia dried blood spot collection cards market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account